Cochrane · systematic review · CD007478
Interventions for cutaneous disease in systemic lupus erythematosus
Hannon, CW, McCourt, C, Lima, HC, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
42
current version
GRADE rated
19
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 23 · 54.8%Very low 0 · 0%Low 10 · 23.8%Moderate 9 · 21.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oral methotrexate versus placebo for cutaneous disease in systemic lupus erythematosus
Population: patients with cutaneous disease in systemic lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: complete clinical response (malar/discoid rash) Oral methotrexate vs placebo | RR 3.57 [1.63, 7.84] | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |
Primary outcome: partial clinical response Oral methotrexate vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: clinical flare Oral methotrexate vs placebo | RR 0.77 [0.32, 1.83] | 1 study · 86 participants | Moderate Downgraded: imprecision |
Secondary outcome: CLASI Oral methotrexate vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: Dermatology quality of life measure Oral methotrexate vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events: severe Oral methotrexate vs placebo | RR 12.05 [0.69, 211.36] | 1 study · 86 participants | Moderate Downgraded: imprecision |
Adverse events: minor Oral methotrexate vs placebo | RR 0.68 [0.39, 1.17] | 1 study · 86 participants | Moderate Downgraded: risk of bias |
Oral hydroxychloroquine versus placebo for cutaneous disease in systemic lupus erythematosus
Population: patients with cutaneous disease in systemic lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: complete clinical response Oral hydroxychloroquine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Primary outcome: partial clinical response Oral hydroxychloroquine vs placebo | RR 7 [0.41, 120.16] | 1 study · 20 participants | Low Downgraded: risk of bias, imprecision |
Secondary outcome: clinical flare Oral hydroxychloroquine vs placebo | RR 0.49 [0.28, 0.89] | 1 study · 47 participants | Moderate Downgraded: imprecision |
Secondary outcome: CLASI Oral hydroxychloroquine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: Dermatology Quality of Life measure Oral hydroxychloroquine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events: severe Oral hydroxychloroquine vs placebo | RR 3.9 [0.19, 78.46] | 1 study · 71 participants | Moderate Downgraded: risk of bias |
Adverse events: minor Oral hydroxychloroquine vs placebo | RR 1.32 [0.24, 7.19] | 1 study · 47 participants | Moderate Downgraded: imprecision |
Oral dehydroepiandrosterone versus placebo for cutaneous disease in systemic lupus erythematosus
Population: patients with cutaneous disease in systemic lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: complete clinical response Oral dehydroepiandrosterone vs placebo | RR 1.11 [1, 1.22] | 1 study · 381 participants | Moderate Downgraded: risk of bias |
Primary outcome: partial clinical response Oral dehydroepiandrosterone vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: clinical flare Oral dehydroepiandrosterone vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: CLASI Oral dehydroepiandrosterone vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: Dermatology Quality of Life measure Oral dehydroepiandrosterone vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events: severe Oral dehydroepiandrosterone vs placebo | RR 0.09 [0.01, 1.66] | 1 study · 381 participants | Moderate Downgraded: risk of bias |
Adverse events: minor Oral dehydroepiandrosterone vs placebo | RR 10.5 [3.26, 33.75] | 1 study · 381 participants | Moderate Downgraded: risk of bias |
Oral chloroquine versus placebo for cutaneous disease in systemic lupus erythematosus
Population: patients with cutaneous disease in systemic lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: complete clinical response Oral chloroquine vs placebo | RR 1.57 [0.95, 2.61] | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Primary outcome: partial clinical response Oral chloroquine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: clinical flare Oral chloroquine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: CLASI Oral chloroquine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: Dermatology Quality of Life measure Oral chloroquine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events: severe Oral chloroquine vs placebo | RR 0.33 [0.01, 7.45] | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Adverse events: minor Oral chloroquine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Oral ciclosporin versus oral azathioprine for cutaneous disease in systemic lupus erythematosus
Population: patients with cutaneous disease in systemic lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: complete clinical response Oral ciclosporin vs oral azathioprine | RR 0.83 [0.46, 1.52] | 1 study · 89 participants | Low Downgraded: risk of bias |
Primary outcome: partial clinical response Oral ciclosporin vs oral azathioprine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: clinical flare Oral ciclosporin vs oral azathioprine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: CLASI Oral ciclosporin vs oral azathioprine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: Dermatology Quality of Life measure Oral ciclosporin vs oral azathioprine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events: severe Oral ciclosporin vs oral azathioprine | RR 0.89 [0.48, 1.65] | 1 study · 89 participants | Low Downgraded: risk of bias |
Adverse events: minor (hirsutism) Oral ciclosporin vs oral azathioprine | RR 9.83 [1.32, 72.95] | 1 study · 89 participants | Low Downgraded: risk of bias |
Oral methotrexate versus oral chloroquine for cutaneous disease in systemic lupus erythematosus
Population: patients with cutaneous disease in systemic lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: complete clinical response Oral methotrexate vs oral chloroquine | RR 1.13 [0.84, 1.5] | 1 study · 25 participants | Low Downgraded: risk of bias, imprecision |
Primary outcome: partial clinical response Oral methotrexate vs oral chloroquine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: clinical flare Oral methotrexate vs oral chloroquine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: Dermatology Quality of Life measure Oral methotrexate vs oral chloroquine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: CLASI Oral methotrexate vs oral chloroquine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events: severe Oral methotrexate vs oral chloroquine | RR 1.73 [0.27, 11.07] | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |
Adverse events: minor Oral methotrexate vs oral chloroquine | RR 3.9 [1.45, 10.51] | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |